ResMed Inc. RMD recently launched AirSense 11, the company’s next-generation positive airway pressure (PAP) device. AirSense 11 is available in the United States, with other countries to follow, and is compatible with all ResMed masks.
AirSense 11 includes new features such as Personal Therapy Assistant and Care Recording to provide personalized advice to PAP users, helping them to facilitate therapy and comfortable use at night. Other features include the availability of remote software updates.
The recent launch will strengthen ResMed’s sleep and respiratory care segment.
Learn more about AirSense 11
AirSense 11 offers interactive step-by-step tutorials through the myAir app allowing patients to configure their device and adjust to therapy pressure. The device’s sleek design, touchscreen and intuitive menu resemble a smartphone, making it easy to use, developed to support increased treatment adherence.
AirSense 11 also provides access to myAir (patient engagement app) and AirView (remote monitoring platform for clinicians). The myAir app tracks the time patients spend using CPAP therapy, the number of sleep apnea events per hour, mask leakage, and the number of times a mask has been removed, providing data nightly breathing sessions, coaching advice and support directly on their phone.
Image source: Zacks Investment Research
AirView offers a secure, cloud-based patient management system for virtual patient monitoring that enables healthcare professionals to quickly access patient data, share clinical information with other healthcare professionals, improve care and reduce costs associated with patient follow-up.
Importance of the launch
New personalized features in AirSense 11 along with the myAir patient engagement app help give people the support they need to use PAP – the gold standard for treating sleep apnea, in comfort and with confidence every night.
The digital health feature guides patients and enables clinicians to deliver quality care to all patients more effectively.
According to a report by Grand View Research, the global sleep apnea devices market size was valued at $ 3.70 billion in 2020 and is expected to reach $ 6.10 billion by 2028 at a CAGR of 6, 2%. Growing awareness of these diseases, increasing availability of state-of-the-art devices, and adherence to supportive therapy by patients are factors driving the market.
Advances in sleep and respiratory care devices
During the fourth fiscal quarter, ResMed reported double-digit revenue growth in its core sleep apnea and respiratory care businesses.
ResMed saw increased device sales due both to the recovery of the flow of sleeping patients after COVID-impacted levels declined in the quarter of the previous year and to increased demand in response the recent product recall by one of ResMed’s competitors. Geographically, device sales in the United States, Canada and Latin America increased by 30%. In the combined markets of Europe, Asia and others, device sales were up 2% at CER. Globally, device sales increased 12% at CER. Additionally, excluding the impact of COVID-related sales in the previous year’s quarter, global device sales rose 46% at TCC.
Shares of the company gained 52.4% in a year compared to the industry’s 12.2% gain.
Zacks rank and choice of keys
Currently the company carries a Zacks Rank # 3 (Hold).
Some better classified actions of the wider medical space are Envista Holding Company NVST, BellRing Brands, Inc. BRBR and Henry Schein, Inc. HSIC, each carrying a Zacks Rank # 2 (Buy). You can see The full list of Zacks # 1 Rank (Strong Buy) stocks here.
Envista Holdings has an estimated long-term earnings growth rate of 26%.
BellRing Brands has an estimated long-term profit growth rate of 22%.
Henry Schein forecast a long-term profit growth rate of 14%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech industry is expected to exceed $ 2.4 trillion by 2028, as scientists develop treatments for thousands of diseases. They are also finding ways to modify the human genome to literally erase our vulnerability to these diseases.
Zacks just released Century of Biology: 7 Biotech Stocks To Buy Now To Help Investors Profit From 7 Stocks That Are Ready to Outperform. Recommendations from previous editions of this report produced gains of + 205%, + 258%, and + 477%. The actions in this report could perform even better.
See these 7 revolutionary actions now >>
Click to get this free report
ResMed Inc. (RMD): Free Stock Analysis Report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
Envista Holdings Corporation (NVST): free share analysis report
BellRing Brands, Inc. (BRBR): Free Stock Analysis Report
To read this article on Zacks.com, click here.
Zacks investment research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.